22.418 articles found

Inhibitors of tgf-r signaling for treatment of cns disorders

BEATE BOGDAHN ULRICH AIGNER LU.

· 2005-02-09

INHIBITORS OF TGF-R SIGNALING FOR TREATMENT OF CNS DISORDERS

BOGDAHN ULRICH, WINKLER JUERGEN, WACHS FRANK PETER, AIGNER LUDWIG, WINNER BEATE.

· 2005-02-09

Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.

Youdim MB, Fridkin M, Zheng H.

Mech Ageing Dev · 2005-02-01

DOI: 10.1016/j.mad.2004.08.023PMID: 15621213

Gene therapy for Parkinson's disease: progress and challenges.

Chen Q, He Y, Yang K.

Curr Gene Ther · 2005-02-01

DOI: 10.2174/1566523052997505PMID: 15638712

The effects of acute loading with levodopa and levodopa with selegiline on blood pressure and plasma norepinephrine levels in chronic Parkinson's disease patients.

Stryjer R, Klein C, Treves TA, Rabey JM.

Acta Neurol Scand · 2005-02-01

DOI: 10.1111/j.1600-0404.2005.00294.xPMID: 15644067

A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.

Johnston TH, Lee J, Gomez-Ramirez J, Fox SH, Brotchie JM.

Exp Neurol · 2005-02-01

DOI: 10.1016/j.expneurol.2004.10.002PMID: 15649479

Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases.

Cui Z, Lockman PR, Atwood CS, Hsu CH, Gupte A, Allen DD, Mumper RJ.

Eur J Pharm Biopharm · 2005-02-01

DOI: 10.1016/j.ejpb.2004.07.009PMID: 15661498

Parkin gene therapy could treat Parkinson's disease.

Butcher J.

Lancet Neurol · 2005-02-01

DOI: 10.1016/s1474-4422(05)00982-8PMID: 15709224

A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.

Parkinson Study Group.

Arch Neurol · 2005-02-01

DOI: 10.1001/archneur.62.2.241PMID: 15710852

Quantitative 1H magnetic resonance spectroscopic imaging determines therapeutic immunization efficacy in an animal model of Parkinson's disease.

Boska MD, Lewis TB, Destache CJ, Benner EJ, Nelson JA, Uberti M, Mosley RL, Gendelman HE.

J Neurosci · 2005-02-01

DOI: 10.1523/jneurosci.4364-04.2005PMID: 15716405

Regulation of neuronal cell death and neurodegeneration by members of the Bcl-2 family: therapeutic implications.

Shacka JJ, Roth KA.

Curr Drug Targets CNS Neurol Disord · 2005-02-01

DOI: 10.2174/1568007053005127PMID: 15723611

Targeting the JNK signaling pathway for stroke and Parkinson's diseases therapy.

Kuan CY, Burke RE.

Curr Drug Targets CNS Neurol Disord · 2005-02-01

DOI: 10.2174/1568007053005145PMID: 15723614